The disclosure provides reagents, methods, and kits, for treating or preventing cancers derived from each of the germ layers (endoderm, mesoderm, ectoderm, neural crest). The reagent encompasses interferon-gamma (IFN-gamma) responsive cancer cells, where the cells are autophagic and non-apoptotic cancer cells, and where the cells express MHC Class II.
